Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Analysis Of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen In Once-Daily Dosing
A sub-analysis of a Phase IIb multinational study(1) with edoxaban(2) - an investigational oral Factor Xa inhibitor - provides insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer bleeding events than patients given edoxaban twice a day (BID). The analysis finds that bleeding associated with edoxaban is most closely correlated with minimum concentration levels of the drug in the blood, and that these trough levels may best predict bleeding events, rather than total exposure or maximum concentration levels.
generic viagra online
Need For Studies On People With Weakened Immune Systems: Vulnerability To Flu And Response To Vaccination
An article published in the August edition of The Lancet Infectious Diseases reports that additional research is required on the vulnerability to the new H1N1 flu strain of different immunosuppressed populations. The possible effectiveness and side-effects of future vaccines also need to be evaluated. The review is the work of Dr Ken M Kunisaki, Minneapolis VA Medical Center, USA, and University of Minnesota, USA, and Dr Edward N Janoff, Univeristy of Colorado Denver School of Medicine and Denver Veterans Affairs Medical Center, USA.
News of the day
Personalized Anti-Cancer Vaccine, BiovaxID(R), Targeting B-Cell Lymphomas Available In Europe On A Named-Patient Basis
Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID®, Biovest"s personalized therapeutic anti-cancer vaccine, is available on a named-patient (compassionate-use) basis in Europe. Following compliance with local regulatory protocols, BiovaxID will be supplied by idis Limited to European healthcare professionals for the treatment of follicular non-Hodgkin"s lymphoma and potentially for other B-cell blood cancers such as chronic lymphocytic leukemia, mantle cell lymphoma and multiple myeloma. Physicians in non-European countries may also contact idis to inquire about the potential availability of BiovaxID, as idis manages named-patient programs in more than 100 countries.
Oncology

Cancer Therapeutics, Inc.'s Partner NanoTherapies, Inc. Utilizes Revolutionary Solution For Disrupting And Treating Cancer

Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced its new partner, NanoTherapies, Inc., is utilizing calcium phosphate nanoparticles to detect and treat cancer. These particles are about 350 times smaller than a human cell while providing both a safe and effective way to transport drugs and imaging materials into diseased cells. NanoTherapies has sole license and patent protection for the fundamental use of calcium phosphate nanoparticles in medical applications for the treatment and detection of blood cancers (all forms of leukemia). NanoTherapies has all rights to manufacturing technologies and intellectual property required to produce pharmaceutical quality drugs at the scale and yield needed for commercial viability. Calcium phosphate is a major component of bones. NanoTherapies" calcium phosphate NanoJackets clear the kidneys and liver without impact. They exit the body via the colon, and their chemical properties enable them to circulate in the bloodstream for prolonged periods yet dissolve in diseased cells, thereby releasing the drug. Metallic, silicon and carbon based nanoparticles cannot make the same claims regarding biocompatibility for humans nor do they have the chemical or physical properties that allow effective drug release in diseased cells. Patient benefits from drugs jacketed with calcium phosphate nanoparticles are immense. Early lab studies show a ten-fold reduction in toxicity with a seven-fold increase in effectiveness for drugs delivered using NT"s technology. This means dramatically reduced side-effects owing to the severe toxicity of cancer drugs and increased effectiveness because the half-life of the drug is increased from minutes to hours. Most cancer drugs kill all the cells they contact and dissipate in less than thirty minutes. NT"s nanojackets encapsulate the drugs for up to thirty hours before being cleared from the body or until the nanoparticle enters a cancerous cell and release the drug. NT"s technology moves drug delivery strategies from carpet-bombing to smart-bombing with the corresponding dramatic decrease in collateral damage. In the same way NT"s nanoparticles deliver drugs to cancerous cells they can also transport imaging dyes that fluoresce under near infrared light to reveal cancerous cells. Imaging cancer at the cellular level enables new methods of early detection of cancer as well as post-treatment and post-operative evaluation. Cancer Therapeutics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009